Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 162

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Trabectedin for Women With Ovarian Carcinoma After Treatment With Platinum and Taxanes Fails

Sessa, Cristiana, De Braud, Filippo, Perotti, Antonella, Bauer, Jean, Curigliano, Giuseppe, Noberasco, Cristina, Zanaboni, Flavia, Gianni, Luca, Marsoni, Silvia, Jimeno, José, D'Incalci, Maurizio, Dall’ó, Elisa, Colombo, Nicoletta · 2005 · Journal of Clinical Oncology

Abstract

Purpose: To assess the efficacy and toxicity of the marine-derived alkaloid trabectedin (ET-743) in patients with advanced ovarian cancer refractory to or experiencing disease relapse after platinum- and taxane-based chemotherapy. Patients and Methods: Fifty-nine patients from four institutions either resistant (n = 30) or sensitive (n = 29) to prior platinum and taxanes were treated with a 3-hour infusion of trabectedin every 3 weeks. Patients were monitored weekly for toxicity and restaged every two cycles for response. Response was assessed according to Response Evaluation Criteria in Solid Tumors Group. Results: The peer-reviewed objective response rate in platinum-sensitive patients was 43% (95% CI, 23% to 65%) with an estimated median time to progression of 7.9 months (95% CI, 7.5 to 14.1 months); in platinum-resistant patients two partial responses were observed. Responses were durable for up to 12.9 months (median, 5 months). The predominant toxicities at the recommended dose of 1,300 μg/m 2 were neutropenia, asthenia, and self-limited increase of aminotransferases never requiring treatment interruption. Conclusion: Trabectedin administered as a 3-hour infusion at 1,300 μg/m 2 is a safe new drug with promising activity in relapsed ovarian cancer, showing a 43% objective response rate in patients with platinum-sensitive disease, which favorably compares with other salvage treatments and warrants additional development either alone or in combination.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2005.09.032

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 162

Metadata

Authors
Sessa, C., De Braud, F., Perotti, A., Bauer, J., Curigliano, G., Noberasco, C., Zanaboni, F., Gianni, L., Marsoni, S., Jimeno, J., D'Incalci, M., Dall’ó, E., & Colombo, N.
Venue
Journal of Clinical Oncology
Published
2005-03-20
Volume
23
Issue
9
Pages
1867-1874
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2157585376
Cited by
162
References
1
FWCI
14.40
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Trabectedin for Women With Ovarian Carcinoma After Treatment With Platinum and Taxanes Fails. https://app.cochat.ai/papers/10.1200/jco.2005.09.032
The paper
Sessa, C., De Braud, F., Perotti, A., Bauer, J., Curigliano, G., Noberasco, C., Zanaboni, F., Gianni, L., Marsoni, S., Jimeno, J., D'Incalci, M., Dall’ó, E., & Colombo, N. (2005). Trabectedin for Women With Ovarian Carcinoma After Treatment With Platinum and Taxanes Fails. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.09.032

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.